berberine has been researched along with Diabetic Nephropathies in 42 studies
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine treatment also alleviated DN-induced changes in the expression of proteins involved in iron transport or iron uptake." | 5.91 | Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress. ( Cai, F; Chen, J; Li, C; Wang, Y; Yue, S; Zhong, Y; Zhu, W, 2023) |
| "Berberine (BBR) is a material extracted from Chinese herbs, which has been used in the treatment of diabetes in Chinese medicine for thousands of years." | 5.46 | Protective effect of berberine on renal fibrosis caused by diabetic nephropathy. ( Li, Z; Zhang, W, 2017) |
| "Berberine (BBR) is a pentacyclic benzylisoquinoline alkaloid that can be found in diversity of medicinal plants." | 2.82 | Protective effects of berberine on various kidney diseases: Emphasis on the promising effects and the underlined molecular mechanisms. ( Abd-Alhameed, EK; Hassanein, EHM; Ibrahim, IM; Mohamed, NM; Ross, SA, 2022) |
| "However, to assess the anti-diabetic nephropathy effects and safety of berberine in a more accurate manner, additional large-scale, long-term, and high-quality preclinical trials are needed to confirm these findings before clinical application." | 2.82 | Protective effect of berberine in diabetic nephropathy: A systematic review and meta-analysis revealing the mechanism of action. ( Hu, S; Li, W; Liu, E; Ma, X; Wang, J; Wei, P; Xiang, J; Zeng, J; Zhang, X; Zhang, Y, 2022) |
| "Berberine has significant curative effect in the treatment of DKD, and the mechanism is related to the reduction of blood sugar, improvement of renal hemodynamics abnormality, regulation of blood lipid profile and the attenuation of systemic and local inflammation." | 2.55 | [Research progress of berberine in treatment of diabetic kidney disease]. ( Dong, H; Lu, FE; Ren, YL; Wang, DK, 2017) |
| "Diabetic nephropathy is a progressive kidney disorder and is pathologically characterized by thickened glomerular and tubular basement membranes, accumulation of the extracellular matrix and increased mesangial hypertrophy." | 2.52 | Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. ( Ding, HH; Ni, WJ; Tang, LQ, 2015) |
| "Berberine treatment also alleviated DN-induced changes in the expression of proteins involved in iron transport or iron uptake." | 1.91 | Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress. ( Cai, F; Chen, J; Li, C; Wang, Y; Yue, S; Zhong, Y; Zhu, W, 2023) |
| "Berberine (BBR) has therapeutic effect on diabetic nephropathy (DN), but its molecular mechanism is not completely clear." | 1.62 | Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells. ( Gan, L; Hu, Y; Liu, L; Xiang, P; Xing, Y; Xu, J; Ye, S; Zhu, J, 2021) |
| "The anti-diabetic nephropathy properties were systematically analyzed in the diabetic db/db mice treated with Met, BBR or with combination of Met and BBR." | 1.62 | Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation. ( Sun, G; Sun, X; Zhang, B; Zhang, C; Zhang, X, 2021) |
| " Thus increasing the oral bioavailability of Pgp substrate-like drugs (PSLDs) remains a great challenge." | 1.62 | Brij-functionalized chitosan nanocarrier system enhances the intestinal permeability of P-glycoprotein substrate-like drugs. ( Chen, QL; Chu, JMT; Hu, YJ; Li, J; Linghu, KG; Wang, YT; Wong, GTC; Xiong, SH; Xiong, W; Yu, H; Zhao, GD, 2021) |
| "Berberine is a plant alkaloid, used in Chinese herbal medicine." | 1.56 | Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis. ( Dong, H; Fang, K; Gong, J; Jiang, M; Lu, F; Qin, X; Su, H; Yu, X; Yuan, F; Yuan, X; Zhao, Y, 2020) |
| " However, the poor bioavailability of berberine limits its clinical applications." | 1.56 | Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy. ( Chen, L; Guan, F; Wang, X; Xiao, D; Zhang, J; Zhang, M; Zhang, Y, 2020) |
| "Berberine could be a promising antidiabetic nephropathy drug through ameliorating renal impairment and inhibiting podocyte dysfunction in diabetic rats, and the underlying molecular mechanisms might be involved in the regulation of the PI3K-Akt signaling pathway." | 1.56 | Berberine ameliorates renal impairment and inhibits podocyte dysfunction by targeting the phosphatidylinositol 3-kinase-protein kinase B pathway in diabetic rats. ( Ding, HH; Ni, WJ; Tang, LQ; Zhou, H, 2020) |
| "Berberine (BBR) has been well characterized to exert renoprotective effects in DN progression." | 1.48 | Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. ( Han, J; Pang, W; Xue, L; Yuan, R; Zhu, L, 2018) |
| "Berberine has been shown to cross the blood-brain barrier and holds promising effect for neuronal damage in diabetes." | 1.48 | Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3β Pathway. ( Chen, J; Chen, Q; Feng, Z; Hang, W; He, B; Wang, S; Wang, X; Wu, N; Xia, L; Zhang, Q; Zhou, X, 2018) |
| "Berberine (BBR) is a material extracted from Chinese herbs, which has been used in the treatment of diabetes in Chinese medicine for thousands of years." | 1.46 | Protective effect of berberine on renal fibrosis caused by diabetic nephropathy. ( Li, Z; Zhang, W, 2017) |
| "Berberine has been shown to exert protective effects against diabetic nephropathy (DN), but the mechanisms involved have not been fully characterized." | 1.43 | Renoprotective effects of berberine and its potential effect on the expression of β-arrestins and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in streptozocin-diabetic nephropathy rats. ( Cai, M; Ding, HH; Liu, S; Ni, WJ; Tang, LQ; Zhang, ST, 2016) |
| "Berberine (BBR) has been shown to have antifibrotic effects in liver, kidney and lung." | 1.43 | Protective Effects of Berberine on Renal Injury in Streptozotocin (STZ)-Induced Diabetic Mice. ( Chi, ZH; He, H; Jiang, Y; Liang, D; Liang, W; Ma, J; Zhang, X, 2016) |
| "Berberine treatment also inhibited renal inflammation, which was associated with inactivation of nuclear factor kappa-light-chain-enhancer of activated B-cell signalling." | 1.42 | Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. ( Dong, X; Huang, XR; Lan, HY; Li, P; Pan, XP; Sun, SF; Wang, H; Wen, YM; Yan, MH; Zhang, HJ; Zhang, L; Zhang, WK; Zhao, TT, 2015) |
| "In the experiments, diabetic nephropathy rats were treated with berberine (0, 50, 100, 200 mg/kg) respectively." | 1.42 | Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats. ( Ding, HH; Ni, WJ; Qiu, YY; Tang, LQ; Zhou, H, 2015) |
| "Berberine (BBR) has preventive effects on diabetes and its complications." | 1.40 | Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. ( Liu, S; Tang, LQ; Wang, FL; Zhang, ST; Zhu, LN, 2014) |
| "Berberine (BBR) has several preventive effects on diabetes and its complications." | 1.40 | Berberine improves kidney function in diabetic mice via AMPK activation. ( Guan, GJ; Nie, HB; Sun, LN; Wang, XL; Zhao, L, 2014) |
| "Berberine treatment for 8 weeks abolished the above changes by upregulating the expression of Gαs protein and downregulating the expression of Gαi protein, increasing cAMP level, and inhibiting MCs proliferation compared with model group." | 1.39 | Berberine ameliorates renal injury by regulating G proteins-AC- cAMP signaling in diabetic rats with nephropathy. ( Liu, S; Lv, F; Tang, LQ; Wang, FL; Zhang, ST; Zhu, LN, 2013) |
| "Berberine (BBR) treatment also effectively inhibits SphK1 activity and S1P production in the kidneys of diabetic models, thus improving renal injury." | 1.38 | Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. ( Huang, H; Huang, J; Huang, K; Lan, T; Liu, P; Liu, W; Peng, J; Shen, X; Wang, S; Xie, X, 2012) |
| "The rat model of diabetic nephropathy was induced by injection of streptozocin (STZ)." | 1.37 | [Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy]. ( Liu, S; Lv, F; Tang, L; Zhang, S, 2011) |
| "One of the main pathological changes in diabetic nephropathy is the renal fibrosis, which includes glomerulosclerosis and tubulointerstitial fibrosis." | 1.36 | Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. ( Huang, H; Jiang, Q; Lan, T; Li, W; Liu, P; Liu, W; Shen, X; Xie, X; Zhang, X, 2010) |
| "Berberine (BBR) was previously found to have beneficial effects on renal injury in experimental diabetic rats." | 1.36 | Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. ( Huang, H; Jiang, Q; Lan, T; Li, W; Liu, P; Liu, W; Shen, X; Xie, X; Xu, S, 2010) |
| "Berberine treatment significantly increased serum SOD activity and decreased the content of MDA compared with diabetic model group (P < 0." | 1.35 | Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. ( Chen, FY; Chen, SR; Deng, YH; Guo, FF; Hei, ZQ; Huang, HQ; Huang, WG; Li, XJ; Liu, PQ; Liu, WH; Nie, H; Tang, FT, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.38) | 29.6817 |
| 2010's | 25 (59.52) | 24.3611 |
| 2020's | 16 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, J | 1 |
| Liu, L | 1 |
| Gan, L | 1 |
| Hu, Y | 1 |
| Xiang, P | 1 |
| Xing, Y | 1 |
| Zhu, J | 1 |
| Ye, S | 1 |
| Zhang, B | 1 |
| Zhang, X | 5 |
| Zhang, C | 1 |
| Sun, G | 1 |
| Sun, X | 1 |
| Ni, WJ | 6 |
| Guan, XM | 2 |
| Zeng, J | 2 |
| Zhou, H | 4 |
| Meng, XM | 1 |
| Tang, LQ | 11 |
| Ma, Z | 2 |
| Zhu, L | 2 |
| Wang, S | 3 |
| Guo, X | 1 |
| Sun, B | 1 |
| Wang, Q | 1 |
| Chen, L | 2 |
| Hassanein, EHM | 1 |
| Ibrahim, IM | 1 |
| Abd-Alhameed, EK | 1 |
| Mohamed, NM | 1 |
| Ross, SA | 1 |
| Hu, S | 1 |
| Wang, J | 1 |
| Liu, E | 1 |
| Xiang, J | 1 |
| Li, W | 3 |
| Wei, P | 1 |
| Zhang, Y | 5 |
| Ma, X | 1 |
| Wang, Y | 1 |
| Yue, S | 1 |
| Cai, F | 1 |
| Zhu, W | 1 |
| Zhong, Y | 1 |
| Chen, J | 2 |
| Li, C | 4 |
| Wang, K | 1 |
| Liu, P | 5 |
| Wang, SF | 1 |
| Zhang, JY | 1 |
| Hu, ZZ | 1 |
| Mei, YQ | 1 |
| Yang, YB | 1 |
| Wang, ZT | 1 |
| Yang, L | 1 |
| Zhai, J | 1 |
| Li, Z | 2 |
| Zhang, H | 1 |
| Ma, L | 2 |
| Zou, J | 1 |
| Li, M | 1 |
| Li, X | 3 |
| Qin, X | 1 |
| Jiang, M | 1 |
| Zhao, Y | 1 |
| Gong, J | 1 |
| Su, H | 1 |
| Yuan, F | 1 |
| Fang, K | 1 |
| Yuan, X | 1 |
| Yu, X | 1 |
| Dong, H | 2 |
| Lu, F | 1 |
| Wang, RY | 1 |
| Xie, YS | 1 |
| Zhang, M | 2 |
| Xiao, D | 1 |
| Zhang, J | 1 |
| Wang, X | 2 |
| Guan, F | 1 |
| Xiao, Y | 2 |
| Liu, Y | 2 |
| Lai, Z | 1 |
| Huang, J | 4 |
| Gong, X | 2 |
| Deng, J | 2 |
| Ye, X | 2 |
| Gui, Z | 1 |
| Xiong, W | 1 |
| Xiong, SH | 1 |
| Chen, QL | 1 |
| Linghu, KG | 1 |
| Zhao, GD | 1 |
| Chu, JMT | 1 |
| Wong, GTC | 1 |
| Li, J | 1 |
| Hu, YJ | 1 |
| Wang, YT | 1 |
| Yu, H | 1 |
| Yang, G | 1 |
| Zhao, Z | 1 |
| Wu, A | 1 |
| Huang, Y | 1 |
| Miao, Y | 1 |
| Yang, M | 1 |
| Ren, YL | 1 |
| Wang, DK | 1 |
| Lu, FE | 1 |
| Zhang, W | 1 |
| Zan, Y | 1 |
| Kuai, CX | 1 |
| Qiu, ZX | 1 |
| Huang, F | 1 |
| Han, J | 1 |
| Yuan, R | 1 |
| Xue, L | 1 |
| Pang, W | 1 |
| He, B | 1 |
| Hang, W | 1 |
| Wu, N | 1 |
| Xia, L | 1 |
| Zhang, Q | 1 |
| Zhou, X | 1 |
| Feng, Z | 1 |
| Chen, Q | 1 |
| Yu, J | 1 |
| Zong, GN | 1 |
| Wu, H | 1 |
| Zhang, KQ | 1 |
| Ding, HH | 4 |
| Li, H | 1 |
| Luo, Y | 1 |
| Xiong, J | 1 |
| Liu, S | 5 |
| Yu, N | 1 |
| Zhang, XL | 1 |
| Chen, XQ | 1 |
| Zhang, ST | 3 |
| Zhu, LN | 3 |
| Wang, FL | 3 |
| Yang, Y | 1 |
| Ni, W | 1 |
| Cai, M | 3 |
| Tang, L | 2 |
| Wei, W | 3 |
| Zhao, L | 1 |
| Sun, LN | 1 |
| Nie, HB | 1 |
| Wang, XL | 1 |
| Guan, GJ | 1 |
| Sun, SF | 1 |
| Zhao, TT | 1 |
| Zhang, HJ | 1 |
| Huang, XR | 1 |
| Zhang, WK | 1 |
| Zhang, L | 1 |
| Yan, MH | 1 |
| Dong, X | 1 |
| Wang, H | 1 |
| Wen, YM | 1 |
| Pan, XP | 1 |
| Lan, HY | 1 |
| Li, P | 1 |
| Qiu, YY | 2 |
| He, H | 1 |
| Liang, D | 1 |
| Jiang, Y | 1 |
| Liang, W | 1 |
| Chi, ZH | 1 |
| Ma, J | 1 |
| Liu, WH | 1 |
| Hei, ZQ | 1 |
| Nie, H | 1 |
| Tang, FT | 1 |
| Huang, HQ | 1 |
| Li, XJ | 1 |
| Deng, YH | 1 |
| Chen, SR | 1 |
| Guo, FF | 1 |
| Huang, WG | 1 |
| Chen, FY | 1 |
| Liu, PQ | 1 |
| Liu, W | 4 |
| Shen, X | 4 |
| Lan, T | 4 |
| Jiang, Q | 2 |
| Xie, X | 4 |
| Huang, H | 4 |
| Xu, S | 1 |
| Lv, F | 2 |
| Zhang, S | 1 |
| Huang, K | 2 |
| Peng, J | 2 |
| Yang, H | 1 |
| Yang, F | 1 |
5 reviews available for berberine and Diabetic Nephropathies
| Article | Year |
|---|---|
Protective effects of berberine on various kidney diseases: Emphasis on the promising effects and the underlined molecular mechanisms.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney | 2022 |
Protective effect of berberine in diabetic nephropathy: A systematic review and meta-analysis revealing the mechanism of action.
Topics: Animals; Berberine; Cholesterol, LDL; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Triglyc | 2022 |
[Research progress of berberine in treatment of diabetic kidney disease].
Topics: Berberine; Blood Glucose; Diabetic Nephropathies; Humans; Kidney; Kidney Failure, Chronic | 2017 |
[Progress for treating diabetic renopathy by berberine hydrochloride in clinical and experimental researches].
Topics: Animals; Berberine; Diabetic Nephropathies; Humans | 2012 |
Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Humans; | 2015 |
37 other studies available for berberine and Diabetic Nephropathies
| Article | Year |
|---|---|
Berberine Acts on C/EBPβ/lncRNA Gas5/miR-18a-5p Loop to Decrease the Mitochondrial ROS Generation in HK-2 Cells.
Topics: Animals; Apoptosis; Berberine; CCAAT-Enhancer-Binding Protein-beta; Diabetes Mellitus, Experimental; | 2021 |
Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation.
Topics: Animals; Berberine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Drug Synerg | 2021 |
Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway.
Topics: Animals; Berberine; Cell Cycle; Cell Division; Cell Proliferation; Diabetes Mellitus; Diabetic Nephr | 2022 |
Berberine protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition involving the inactivation of the NLRP3 inflammasome.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Glucose; Infl | 2022 |
Treatment of berberine alleviates diabetic nephropathy by reducing iron overload and inhibiting oxidative stress.
Topics: Animals; Berberine; Diabetes Mellitus; Diabetic Nephropathies; Iron; Iron Overload; Kidney; Oxidativ | 2023 |
[Quality evaluation of Compound Cheqian Tablets based on UPLC-Q-TOF-MS/MS, network pharmacology and "double external standards" QAMS].
Topics: Berberine; Chromatography, High Pressure Liquid; Diabetic Nephropathies; Drugs, Chinese Herbal; Huma | 2023 |
Coptisine ameliorates renal injury in diabetic rats through the activation of Nrf2 signaling pathway.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heme Oxygenase (Decycli | 2020 |
Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis.
Topics: Animals; Berberine; Diabetes Mellitus; Diabetic Nephropathies; Homeostasis; Humans; Mice; Mitochondr | 2020 |
Berberine mitigates high glucose-induced podocyte apoptosis by modulating autophagy via the mTOR/P70S6K/4EBP1 pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Autophagy; Berberine; Cell Cycle Proteins; | 2020 |
Highly bioavailable berberine formulation ameliorates diabetic nephropathy through the inhibition of glomerular mesangial matrix expansion and the activation of autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Berberine; Diabetes Mellitus, Experimental; Diabe | 2020 |
An integrated network pharmacology and transcriptomic method to explore the mechanism of the total Rhizoma Coptidis alkaloids in improving diabetic nephropathy.
Topics: Alkaloids; Animals; Berberine; Computational Biology; Diabetic Nephropathies; Drugs, Chinese Herbal; | 2021 |
Epiberberine ameliorated diabetic nephropathy by inactivating the angiotensinogen (Agt) to repress TGFβ/Smad2 pathway.
Topics: Angiotensinogen; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibros | 2021 |
Brij-functionalized chitosan nanocarrier system enhances the intestinal permeability of P-glycoprotein substrate-like drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Berberine; Chitosan; Diabetic Neph | 2021 |
Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice.
Topics: Animals; Berberine; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diseas | 2017 |
Protective effect of berberine on renal fibrosis caused by diabetic nephropathy.
Topics: Actins; Animals; Berberine; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Experimental; Diabet | 2017 |
Berberine Ameliorates Diabetic Neuropathy: TRPV1 Modulation by PKC Pathway.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; | 2017 |
Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Male; NF-kappa B; Rats; | 2018 |
Berberine Alleviates Tau Hyperphosphorylation and Axonopathy-Associated with Diabetic Encephalopathy via Restoring PI3K/Akt/GSK3β Pathway.
Topics: Animals; Axons; Berberine; Cells, Cultured; Chromones; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2018 |
Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice.
Topics: Animals; Apoptosis; Berberine; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; H | 2019 |
Berberine ameliorates renal impairment and inhibits podocyte dysfunction by targeting the phosphatidylinositol 3-kinase-protein kinase B pathway in diabetic rats.
Topics: Animals; Berberine; Blood Glucose; Diabetic Nephropathies; Disease Models, Animal; Male; Phosphatidy | 2020 |
[Regulatory effect of berberine on unbalanced expressions of renal tissue TGF-beta1/SnoN and smad signaling pathway in rats with early diabetic nephropathy].
Topics: Animals; Berberine; Diabetic Nephropathies; Gene Expression; Humans; Kidney; Male; Nerve Tissue Prot | 2012 |
Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dinoprostone; Disease M | 2014 |
The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats.
Topics: Animals; Berberine; Cyclic AMP; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Respon | 2014 |
Berberine improves kidney function in diabetic mice via AMPK activation.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cell Line; Diabetes Mellitus, Experimental; Diabe | 2014 |
Renoprotective effect of berberine on type 2 diabetic nephropathy in rats.
Topics: Animals; Berberine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Inflammation Mediators; Male; | 2015 |
Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats.
Topics: Animals; Berberine; Blood Glucose; Blotting, Western; Collagen Type IV; Cytoprotection; Diabetes Mel | 2015 |
Renoprotective effects of berberine and its potential effect on the expression of β-arrestins and intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in streptozocin-diabetic nephropathy rats.
Topics: Animals; Berberine; beta-Arrestins; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nep | 2016 |
Protective Effects of Berberine on Renal Injury in Streptozotocin (STZ)-Induced Diabetic Mice.
Topics: Animals; Berberine; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epit | 2016 |
Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Proliferation; Diabetic Nephropathies; Down-Reg | 2017 |
Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase.
Topics: Aldehyde Reductase; Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Mal | 2008 |
Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Extrac | 2010 |
Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway.
Topics: Albuminuria; Animals; Berberine; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephro | 2010 |
[Effect of berberine on expression of transforming growth factor-beta1 and type IV collagen proteins in mesangial cells of diabetic rats with nephropathy].
Topics: Animals; Berberine; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene | 2011 |
Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Fibron | 2012 |
Berberine suppresses high glucose-induced TGF-β1 and fibronectin synthesis in mesangial cells through inhibition of sphingosine kinase 1/AP-1 pathway.
Topics: Actins; Animals; Berberine; Cells, Cultured; Diabetic Nephropathies; Dose-Response Relationship, Dru | 2012 |
Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cyclic AMP; Diabetes Mellitus, Experimental; Diabeti | 2013 |
Berberine ameliorates renal injury by regulating G proteins-AC- cAMP signaling in diabetic rats with nephropathy.
Topics: Adenylyl Cyclases; Animals; Berberine; Blood Glucose; Cell Proliferation; Collagen Type IV; Connecti | 2013 |